Detalhe da pesquisa
1.
Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.
J Liposome Res
; 32(4): 386-395, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35225132